Key Takeaways
  • Thymosin beta-4 is a natural 43 amino acid peptide found in nearly every mammalian cell. TB-500 is not the same molecule: products sold under that name are usually a synthetic seven residue fragment, acetylated LKKTETQ, corresponding to positions 17 to 23 of the parent peptide.
  • Thymosin beta-4 and its derivatives are prohibited at all times by the World Anti-Doping Agency, and thymosin synthetic fragments appear as a banned anabolic agent on the FEI 2026 Equine Prohibited Substances List. Published equine doping research states that the substance is also forbidden by the International Federation of Horseracing Authorities.
  • Equine laboratories can confirm the synthetic fragment at 0.02 ng/mL in plasma and 0.01 ng/mL in urine, and a 2025 population study described a strategy based on detecting a non-natural synthesis impurity in horse plasma.
  • The best documented thymosin beta-4 doping case is a human one: the Court of Arbitration for Sport sanctioned 34 Australian Football League players in January 2016, on non-analytical evidence, with none of them ever having tested positive.
  • There is no approved veterinary product containing TB-500 anywhere, and a PubMed search returns no published efficacy, safety or pharmacokinetic study of TB-500 in dogs. The animal literature is almost entirely rodent work using full length thymosin beta-4.
  • A 2013 regulatory laboratory bulletin found that many products labeled TB-500 contained no thymosin beta-4 or any peptide derived from it, which makes any claim about what an unregulated vial will do in an animal unverifiable.
  • Any decision about an injured horse or dog belongs with a licensed veterinarian who can examine the animal. This article is educational and is not veterinary advice.

What is TB-500, and how is it different from thymosin beta-4?

Search for TB-500 for horses or TB-500 for dogs and you will find confident claims about tendon repair, faster recovery and renewed soundness. Almost none of those claims rest on a published study in the species being discussed. Before looking at the evidence, it is worth being precise about what the molecule actually is, because two different substances are routinely treated as one.

Thymosin beta-4 (often written Tβ4) is an endogenous peptide of 43 amino acids with a molecular weight of roughly 4,963 daltons. It is present in essentially all mammalian cells, it is highly conserved between species, and its main biochemical job is to bind and sequester actin, which influences how cells reorganize their cytoskeleton and migrate. A 2025 equine doping study described it as ubiquitous, highly conserved and abundant among mammals, with a critical role in cytoskeleton organization.

TB-500 is a trade name, not a biological entity. The material sold under that label is normally a synthetic heptapeptide, acetylated LKKTETQ, which corresponds to residues 17 to 23 of thymosin beta-4 with an artificial acetyl group added to the N-terminus. Its molecular weight is about 889 g/mol, roughly one fifth of the parent peptide. The 2012 equine doping control paper that established the reference detection method stated the point plainly: the key ingredient of TB-500 is the peptide LKKTETQ with artificial acetylation of the N-terminus.

This distinction matters for every claim that follows. A short acetylated fragment and a full length 43 residue peptide are different molecules with different stability, different distribution and different biological behavior. When a marketing page cites a rodent cardiac study to support what a vial of TB-500 will do in a horse, it is almost always citing work performed with full length thymosin beta-4, not with the fragment in the vial. Our TB-500 reference guide covers the chemistry in more detail.

In short, the fragment borrows the reputation of the parent peptide. That borrowing is the single most common source of confusion in this topic.

How did TB-500 end up in horse racing?

The arrival of this peptide in equine sport did not follow the usual path of a veterinary medicine. There was no approval, no label, no indication and no controlled equine trial. Instead, the compound reached stables through the grey market in research peptides, carried by claims about tissue repair and tendon healing that are extremely attractive in an industry where soft tissue injury ends careers.

Regulators noticed the pattern early. In July 2013, the Racing Medication and Testing Consortium issued a drug bulletin on thymosin beta-4 after receiving numerous inquiries about products purported to contain it, or substances marketed for use in horses and referred to generically as TB-500. That bulletin recommended that any administration of TB-500 be treated as a prohibited act, and that a finding for the substance or its metabolites be treated as a finding for a prohibited substance, with the most severe penalty category applied.

Analytical chemists moved at the same time. The Hong Kong Jockey Club laboratory published a liquid chromatography mass spectrometry method for the synthetic fragment in equine urine and plasma in 2012, specifically framed as doping control work. A method is only developed when a regulator believes a substance is circulating. Publication in 2012 and a regulatory bulletin in 2013 tell you that the compound was already in use in the racing world more than a decade ago.

Two features made it appealing to anyone willing to break the rules. First, the parent peptide is endogenous, which creates a plausible argument that any measurement is simply natural background. Second, early marketing suggested it was undetectable. Both assumptions have since been dismantled by the laboratories, as the detection section below explains.

The commercial context has not improved. The 2025 equine population study noted that despite its non-authorized status as a medicine, numerous products are available online claiming to contain synthetic acetylated fragments of thymosin beta-4 or the parent peptide itself.

Which doping cases involving thymosin beta-4 are actually documented?

This is where careful sourcing matters, because the internet is full of confident statements about trainers banned in three countries, and very few of them come with a verifiable case file. We will only describe what can be checked.

The clearest documented thymosin beta-4 doping decision anywhere is not equine. In January 2016, the Court of Arbitration for Sport found that 34 past and present Australian Football League players had used thymosin beta-4 during a supplements program run at Essendon Football Club in 2011 and 2012. The decision overturned an earlier not guilty finding by the AFL Anti-Doping Tribunal after an appeal by the World Anti-Doping Agency, and imposed two year periods of ineligibility commencing 31 March 2015. Critically, none of the players had ever returned a positive test: the case was built on documentary and testimonial evidence, not on an analytical finding.

That case is relevant to horse owners for two reasons. It demonstrates that thymosin beta-4 has genuinely been administered to athletes rather than merely discussed, and it demonstrates that an anti-doping case can be proven without a laboratory positive, which removes the comfort of assuming that a clean test means a clean file.

On the equine side, the regulatory and scientific record is solid even where individual case files are not publicly archived in a way we can verify. The 2025 study in Drug Testing and Analysis states that the substance has been misused in equine sports despite being forbidden by the International Federation of Horseracing Authorities, the FEI and WADA, and the authors went on to build a detection strategy precisely because of that misuse. The 2012 Hong Kong method paper describes confirming the fragment and its metabolites in samples from horses administered the product under controlled conditions.

We deliberately do not name individual trainers or horses here. Where a specific disqualification is widely repeated online without a retrievable ruling, the honest position is that the regulatory prohibition is documented and the individual anecdote is not.

Is TB-500 prohibited for horses under racing and equestrian rules?

Yes, and the prohibition operates at several independent levels. Anyone considering this compound for a competition animal should understand that the question is not whether it is banned, but how many separate rulebooks it violates.

For human sport, the World Anti-Doping Agency lists thymosin beta-4 and its derivatives, naming TB-500 as the example, within section S2 covering peptide hormones, growth factors, related substances and mimetics. It is a non-specified substance prohibited at all times, in and out of competition.

For equestrian disciplines, the FEI 2026 Equine Prohibited Substances List includes thymosin synthetic fragments as a banned substance classified as an anabolic agent. Banned substances under the FEI framework have no place in the competition horse at any time, which is a stricter standard than the controlled medication category used for therapeutic drugs with legitimate veterinary use.

For racing in the United States, the Horseracing Integrity and Safety Authority program administered by the Horseracing Integrity and Welfare Unit covers a large catalogue of prohibited substances, with 1,365 substances listed and categorized in the technical document HISA submitted to the Federal Trade Commission. That list is structured into categories that include non-approved substances, covering compounds that lack approval by a human or veterinary regulatory authority. We could not verify that TB-500 appears by name in the published list, and we will not claim that it does. What is verifiable is that an unapproved peptide with no legitimate veterinary indication sits squarely within the logic of that category, and that United States racing has treated it as prohibited since the 2013 industry bulletin recommending maximum penalty treatment. Before the federal program existed, several state racing commissions named thymosin directly in their medication rules.

No regulatory authority has approved any product containing TB-500 as a veterinary medicine. There is no FDA approved animal drug, no European Medicines Agency authorization, and therefore no label, no quality specification and no approved indication for horses or dogs. Legal status for possession and sale varies by jurisdiction, but the sporting prohibition does not vary.

How do equine anti-doping laboratories detect it?

The claim that this peptide is undetectable is obsolete by more than a decade. Equine laboratories solved the analytical problem in two stages, and the second stage closed the loophole that the endogenous nature of the parent peptide appeared to offer.

The first stage targeted the synthetic fragment itself. In the reference method published in the Journal of Chromatography A in 2012, the parent peptide and its metabolites were isolated from equine urine or plasma by solid phase extraction on ion exchange cartridges, then analyzed by liquid chromatography mass spectrometry. Acetylated LKKTETQ could be detected and confirmed at 0.02 ng/mL in equine plasma and 0.01 ng/mL in equine urine, and the method successfully confirmed the parent fragment and its metabolites in samples from horses that had received a TB-500 product. Those are vanishingly small concentrations, which is why metabolite targeting rather than parent compound alone is the standard approach.

The second stage addressed the harder question: how to interpret a measurement of a peptide that every horse produces naturally. The 2025 population study in Drug Testing and Analysis established baseline behavior in a horse population and reported that thymosin beta-4 concentration did not depend significantly on sex, age or breed. It also identified a crucial pre-analytical trap: concentrations increase significantly and rapidly in plasma stored at 4°C when the plasma is not separated from the blood cells, because cell lysis releases the intracellular peptide. Sample handling, in other words, can manufacture an apparent elevation.

Most importantly, the same work showed that a non-natural synthesis impurity can be detected in equine plasma after a single administration of a thymosin beta-4 containing product. An impurity that only exists because the material was made in a factory is a far more robust marker than a concentration threshold, since no amount of argument about natural variation can explain it.

The practical consequence for owners and trainers is simple. Administration leaves a chemical signature that targeted methods are designed to find, and the strict liability framework of equine anti-doping means the person responsible for the horse carries the consequence regardless of intent.

What does the animal research actually show?

There is a real body of preclinical work on thymosin beta-4, and it deserves to be described accurately rather than either inflated or dismissed. Nearly all of it was performed in rodents, with full length thymosin beta-4, in acute injury models, using pharmaceutical grade material.

In wound healing, the foundational study was published in the Journal of Investigative Dermatology in 1999. In a rat full thickness wound model, thymosin beta-4 applied topically or given intraperitoneally increased reepithelialization by 42 percent over saline controls at four days, and by as much as 61 percent at seven days after wounding. Later rodent work reported organization of connective tissue and reduced appearance of myofibroblasts, which is relevant to scar quality rather than to speed alone.

In cardiology, the influential paper appeared in Nature in 2004. Thymosin beta-4 promoted myocardial and endothelial cell migration, enhanced cardiomyocyte survival in culture, and formed a functional complex with PINCH and integrin linked kinase that activated the survival kinase Akt. After coronary artery ligation in mice, treated animals showed upregulated integrin linked kinase and Akt activity, enhanced early myocyte survival and improved cardiac function. A 2010 review in the Annals of the New York Academy of Sciences summarized this animal work as the foundation for subsequent dermal, corneal and cardiac repair trials in humans, and a 2026 scoping review in Applied Sciences reached a similar conclusion about the state of the evidence for both the parent peptide and the fragment.

Human development of the parent peptide also tells a cautionary story. Injectable thymosin beta-4 for acute myocardial infarction was registered on ClinicalTrials.gov as NCT01311518 and carries a status of withdrawn, so the trial never produced efficacy data. Decades after the first rodent results, there is still no approved thymosin beta-4 medicine for humans or animals.

For horses specifically, the published literature we could locate is analytical rather than therapeutic. Searches return doping control methodology and population studies, not controlled trials of TB-500 for tendon or ligament injury in horses. Claims that a blinded equine tendon trial has demonstrated benefit circulate on commercial websites, and we were unable to verify such a trial in the indexed literature. Absence of published evidence is not proof of absence of effect, but it does mean that no one can honestly tell a horse owner what to expect.

Is TB-500 safe for dogs?

The honest answer is that nobody knows, and that is not a rhetorical hedge. It reflects an almost complete absence of canine data.

A search of the indexed literature returns no published efficacy study, no safety study and no pharmacokinetic study of TB-500 in dogs. The only canine appearance of the parent peptide that we could verify is descriptive: a 2013 paper in Peptides characterized thymosin beta-4 in the saliva of several mammals and reported its identification in dog saliva for the first time, alongside rat, horse and bovine saliva. That tells us dogs make the peptide. It tells us nothing about injecting a synthetic fragment into one.

The missing information is exactly the information that determines safety. In dogs there is no published data on absorption or bioavailability by any route, no half-life, no clearance pathway, no tissue distribution, no immunogenicity assessment, no interaction data with common canine medications, and no toxicology at any exposure level. There is no approved veterinary product, so there is no manufacturer safety file either. Species differences in peptide handling are not a theoretical concern: they are the normal case.

One additional consideration deserves careful, non-alarmist phrasing. Thymosin beta-4 influences cell migration and angiogenesis, the same processes that tumors exploit. In a 2003 study in the Journal of the National Cancer Institute, mouse melanoma cells engineered to overexpress thymosin beta-4 produced a mean of 46.7 metastatic lung nodules compared with 10.9 for control cells. That experiment overexpressed the gene inside tumor cells and did not administer TB-500 to a healthy animal, so it does not show that the fragment causes cancer. Other work has reported tumor suppressive effects in different cancer types, so the literature is not uniform. What it does show is that the question of tumor behavior is biologically open, and in a population such as older dogs, where neoplasia is common and often undetected, an open question of that kind is a reason for caution rather than reassurance.

If your dog has an injury that is not healing, the appropriate step is a veterinary examination, imaging where indicated, and an evidence based plan from a licensed veterinarian. Unapproved peptides bought online are not a substitute for a diagnosis. For broader context on how to think about peptide safety generally, see are peptides safe.

What about combining BPC-157 and TB-500 in dogs?

The pairing of BPC-157 and TB-500 is heavily promoted for recovery, and the combination is one of the most searched questions in the canine context. The evidence picture is weaker than for either compound alone, not stronger.

BPC-157 is a 15 amino acid sequence derived from a gastric protein, with an extensive rodent literature on tendon, ligament, muscle and gastrointestinal injury models. It has no completed Phase III human trial, no veterinary approval, and the overwhelming majority of its supporting work comes from a small number of research groups. We compare the two peptides directly in BPC-157 vs TB-500.

When two unapproved compounds are combined, the unknowns multiply rather than cancel out. There is no published study of the combination in dogs, no published study of the combination in horses, and no pharmacological rationale that has been tested in either species. Any claimed synergy between them in a companion animal is an extrapolation from rodent experiments performed with each compound separately, usually at exposures and by routes that bear no documented relationship to what is being sold.

Blended vials introduce a further problem. A single vial containing two peptides doubles the number of ways a product can be mislabeled, understrength, degraded or contaminated, and it makes any adverse event impossible to attribute. If a dog develops an injection site reaction, lethargy or a change in appetite after receiving a blend, neither the owner nor the veterinarian can determine which component, or which impurity, was responsible.

None of this is an argument that the compounds are inert. It is an argument that a companion animal is a poor place to run an uncontrolled experiment. A veterinarian can offer options with actual evidence behind them, including physiotherapy, controlled exercise programs, imaging guided diagnosis, licensed anti-inflammatory protocols and, where appropriate, regenerative approaches that have been studied in the species.

What risks come from unregulated products sold for animals?

Even if you set aside every pharmacological question, there remains the question of what is actually inside the vial. On this point the regulatory record is unusually direct.

The 2013 drug bulletin issued by the Racing Medication and Testing Consortium reported laboratory analysis of products marketed as TB-500. Many of the substances labeled TB-500 did not contain any thymosin beta-4 or any peptide derived from it, while some did contain acetylated LKKTETQ, the purported active component. A product category in which a significant share of samples contain none of the advertised peptide cannot support any claim about outcomes, because the exposure itself is unknown.

The quality risks are the familiar ones for research chemicals sold outside pharmaceutical regulation. There is no enforced identity or purity specification, no sterility assurance for an injectable, no endotoxin testing, no stability data, and no batch traceability. Residual synthesis reagents and process impurities are not characterized for the buyer, which is ironic given that it is precisely a synthesis impurity that anti-doping scientists now use to prove administration.

Then there are the consequences that are entirely predictable. For a competition horse, administration risks a prohibited substance finding, disqualification of results, financial penalty and suspension of the responsible person, under a strict liability framework that does not require proof of intent. Contamination of a shared yard, shared equipment or a shared vehicle can expose horses whose connections never agreed to anything. For a dog, the risk is borne by an animal that cannot report pain, nausea or a worsening lesion, and by an owner who may delay a real diagnosis while waiting for an unapproved product to work.

Reported adverse effects in humans using these products are documented only through anecdote and surveillance rather than controlled trials, which is itself a warning sign about the quality of the available safety signal. We summarize what is and is not known in TB-500 side effects. This article is educational and does not constitute veterinary or medical advice.

Why is there no reliable guidance for using TB-500 in animals?

A very large share of the search traffic on this topic looks for a chart: a simple table organized by body weight for a horse or a dog. We do not publish one, and the reason is not editorial squeamishness. It is that the inputs required to construct such a table do not exist for either species.

Deriving a defensible administration scheme for an animal requires, at minimum, species specific pharmacokinetics, a demonstrated exposure response relationship, a safety margin established in toxicology studies, a validated route of administration, and a product of known identity and purity. For TB-500 in dogs, none of these exist in the published literature. For horses, what exists is analytical: methods that prove the substance was given, and population data that establish natural background. Neither tells you anything about a therapeutic window.

Charts that circulate online are typically back calculated from human bodybuilding forum practice by simple weight scaling. That method is pharmacologically unsound. Peptide clearance, protease activity, plasma protein binding and tissue distribution do not scale linearly with body mass between species, and a horse is not a 500 kilogram human any more than a beagle is a small one. A number produced that way carries the appearance of precision with none of the substance.

There is also a regulatory answer that sits above the scientific one. In competition horses, the substance is prohibited at all times under the FEI framework and under the racing rules described above, so the only compliant quantity is none. In dogs, there is no approved product to administer, which means any use is an off label use of an unapproved substance, a decision that belongs to a licensed veterinarian who has examined the animal, not to a website.

If you came here looking for a number, the useful takeaway is that the absence of one is the finding. Discuss your horse's or dog's injury with your veterinarian, ask what evidence supports each option offered, and treat any source that provides confident animal quantities for this peptide as a source that has stopped checking its own claims. Our TB-500 monograph sets out the full state of the research.

Recommended products

Research peptides selected for quality and purity:

🏆

Where to buy this peptide?

We analyzed the best suppliers to help you find a quality, lab-tested product.

See our selection →

Test your knowledge

Quick quiz · 6 questions

Frequently Asked Questions

Is TB-500 approved for use in horses or dogs?
No. There is no approved veterinary product containing TB-500 in the United States, the European Union or any other major jurisdiction, which means there is no label, no approved indication, no quality specification and no manufacturer safety file for either species. Material sold under the name is supplied for laboratory research use only. Any administration to an animal is use of an unapproved substance and is a decision for a licensed veterinarian who has examined that animal, not something to be taken from a website.
Will TB-500 show up on an equine drug test?
It can. A liquid chromatography mass spectrometry method published in 2012 confirmed the synthetic acetylated LKKTETQ fragment at 0.02 ng/mL in equine plasma and 0.01 ng/mL in equine urine, and also targeted its metabolites. A 2025 population study went further by showing that a non-natural synthesis impurity can be detected in horse plasma after a single administration of a thymosin beta-4 containing product. Claims that the peptide is undetectable in horses have been obsolete for more than a decade, and equine anti-doping operates on strict liability, so the responsible person carries the consequence regardless of intent.
Has TB-500 been studied in dogs?
Not therapeutically. A search of the indexed literature returns no published efficacy, safety or pharmacokinetic study of TB-500 in dogs. The one verifiable canine mention of the parent peptide is descriptive: a 2013 paper in Peptides identified thymosin beta-4 in dog saliva, which confirms only that dogs produce the natural peptide. There is no published canine data on absorption, half-life, clearance, immunogenicity, drug interactions or toxicology, so no one can give an evidence based answer about safety in dogs.
Is TB-500 the same thing as thymosin beta-4?
No, and conflating them is the most common error in this topic. Thymosin beta-4 is a natural 43 amino acid peptide of about 4,963 daltons present in nearly all mammalian cells. TB-500 is a trade name for a synthetic seven residue fragment, acetylated LKKTETQ, corresponding to positions 17 to 23 of the parent peptide, with a molecular weight near 889 g/mol. Almost all of the rodent wound healing and cardiac research cited in marketing material used the full length natural peptide, not the short synthetic fragment in the vial.
What should I do if my dog or horse has an injury that is not healing?
Start with a veterinary examination rather than a product. A veterinarian can establish a diagnosis, use imaging where indicated, and propose options that have actually been studied in the species, including controlled exercise programs, physiotherapy, licensed medications and, where appropriate, regenerative approaches with published equine or canine evidence. For a competition horse, also ask specifically about the status of anything proposed under the FEI and racing rules, since banned substances are prohibited at all times and a therapeutic intention does not change a prohibited finding. This article is educational and is not veterinary advice.

Sources

  1. Delcourt V, et al. (2025). Equine Doping Controls of Thymosin β4: A Population Study and Strategy for Misuse Detection. Drug Testing and Analysis. (PubMed)
  2. Ho ENM, Kwok WH, Lau MY, Wong ASY, Wan TSM, et al. (2012). Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography mass spectrometry. Journal of Chromatography A. (PubMed)
  3. Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. (PubMed)
  4. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. (PubMed)
  5. Cha HJ, Jeong MJ, Kleinman HK (2003). Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute. (PubMed)
  6. de Sousa-Pereira P, Abrantes J, Colaço B, Castagnola M, Amado F, Esteves PJ, Vitorino R (2013). Characterization of thymosin β4 in mammals' saliva. Peptides. (PubMed)
  7. Philp D, et al. (2010). Animal studies with thymosin β4, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences. (nyaspubs.onlinelibrary.wiley.com)
  8. McGuire F, Hughes E, Maak T, Cushman DM (2026). Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Applied Sciences. (mdpi.com)
  9. Fédération Equestre Internationale (2026). 2026 Equine Prohibited Substances List (thymosin synthetic fragments, banned, anabolic agent). FEI Clean Sport for Horses. (inside.fei.org)
  10. Racing Medication and Testing Consortium (2013). Thymosin β4 Drug Bulletin (TB-500): laboratory analysis and recommended regulatory treatment. RMTC Tactical Research Committee. (rmtcnet.com)
  11. Horseracing Integrity and Safety Authority (2023). HISA Prohibited Substances List, Banned Substances (1,365 prohibited substances submitted to the Federal Trade Commission). Horseracing Integrity and Welfare Unit. (assets.hiwu.org)
  12. RegeneRx Biopharmaceuticals (2011). A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 (RGN-352) for Treating Acute Myocardial Infarction, NCT01311518, status withdrawn. ClinicalTrials.gov. (clinicaltrials.gov)
  13. Court of Arbitration for Sport / Australian Football League (2016). CAS decision sanctioning 34 past and present players for use of thymosin beta-4, two year ineligibility from 31 March 2015. AFL / Court of Arbitration for Sport. (afl.com.au)

This content is for informational and educational purposes only. It does not constitute medical advice. Consult a healthcare professional before making any decisions. Read our full medical disclaimer